Literature DB >> 2056014

A University of California State-supported AIDS research award program--a unique state and university partnership in AIDS research.

N K Das1, C L Hopper, M Jencks, J Silva.   

Abstract

This article describes the State-supported University of California AIDS research award program and its major accomplishments. It shows how a partnership between a University and a State resulted in the formation of a successful, efficient, and cost-effective AIDS research award program. This program provides funds for rapid testing of investigator-initiated meritorious research ideas, new drugs, and treatment modalities. Funds were also utilized to establish three AIDS Clinical Research Centers, which evolved into regional consortia that coordinate trials of new drugs and other modalities. This program succeeded in involving investigators whose efforts have led to excellent medical care, advanced technologies, and new drugs for treating AIDS and AIDS-related diseases. The University remains committed to continuing support of all areas of AIDS research, emphasizing drug and vaccine development, pediatric AIDS, and AIDS prevention studies in groups at high risk for HIV infection.

Entities:  

Mesh:

Year:  1991        PMID: 2056014     DOI: 10.1007/bf00917742

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  Occupational risk of HIV, HBV and HSV-2 infections in health care personnel caring for AIDS patients.

Authors:  T L Kuhls; S Viker; N B Parris; A Garakian; J Sullivan-Bolyai; J D Cherry
Journal:  Am J Public Health       Date:  1987-10       Impact factor: 9.308

2.  Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; P C Hopewell
Journal:  Chest       Date:  1989-04       Impact factor: 9.410

3.  Long-term observation of baboons, rhesus monkeys, and chimpanzees inoculated with HIV and given periodic immunosuppressive treatment.

Authors:  W J Morrow; J Homsy; J W Eichberg; J Krowka; L Z Pan; I Gaston; H Legg; N Lerche; J Thomas; J A Levy
Journal:  AIDS Res Hum Retroviruses       Date:  1989-04       Impact factor: 2.205

4.  Significant changes in HIV antigen level in the serum of patients treated with azidothymidine.

Authors:  R E Chaisson; J P Allain; M Leuther; P A Volberding
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

5.  AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells.

Authors:  J A Levy; J Shimabukuro; T McHugh; C Casavant; D Stites; L Oshiro
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

6.  Molecular cloning of AIDS-associated retrovirus.

Authors:  P A Luciw; S J Potter; K Steimer; D Dina; J A Levy
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

7.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome.

Authors:  J E Groopman; R T Mitsuyasu; M J DeLeo; D H Oette; D W Golde
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

8.  The antiviral effect of zidovudine and ribavirin in clinical trials and the use of p24 antigen levels as a virologic marker.

Authors:  S A Spector; C Kennedy; J A McCutchan; S A Bozzette; R G Straube; J D Connor; D D Richman
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

9.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.